Your Path to Hope Resources

For the first time in 12 years, glioblastoma patients in Canada have a new treatment option.

The Ivy Brain Tumor Center at Barrow Neurological Institute and SonALAsense announced positive results in their first-in-human Phase 0/1 clinical trial of SDT in recurrent glioblastoma patients. The initial results were presented at the European Society for Medical Oncology Congress today by Nader Sanai, MD, Director of the Ivy Brain Tumor Center. “The Ivy Center’s Phase 0/1 study has shown a promising translation of the preclinical results of SDT in patients with glioblastoma.

Dr. Nick Avgeropoulos, Orlando Health – UF Cancer Center, is confident that in many clinical trials a treatment was found that could work, however, they may not have been the exact right dose or for …

Dr. Khagi from UNC Neuro-Oncology Program breaks down a glioblastoma diagnosis from imaging to clinical trials to new research.

Earlier today, GT Medical Technologies of Tempe, Arizona announced patients with newly diagnosed malignant tumors are now eligible to receive FDA-cleared GammaTile® Therapy in addition to patients with recurrent brain tumors.

Written by Optune® Ambassador Ashley M.J. Hello everyone, my name is Ashley. If I had to describe myself in one word, it would be “grateful”. I love my faith. I love my family. I love …

Written by Optune® Ambassador Gill D. Hi, everyone, my name is Gill. I’d like to take this opportunity to thank Novocure for making it possible for me to share my story with you today. I’m …

Written by Optune® Ambassador Eric C. My father used to say to me when I was a kid, “Eric, don’t be helpless.” Throughout my life I have often reflected on his words when facing difficulties, …

Scientists at MIT have devised new methods of delivering medication to hard-to-treat brain tumors like glioblastoma that use a kind of tiny molecule called “nanoparticles.” The MIT scientists had a pair of drugs that they …